IMGN ImmunoGen Inc.

2.44
+0.13  (+6%)
Previous Close 2.31
Open 2.3
Price To Book -5.42
Market Cap 365,718,951
Shares 149,884,816
Volume 827,954
Short Ratio
Av. Daily Volume 1,665,977
Stock charts supplied by TradingView

NewsSee all news

  1. ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO

    FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of

  2. ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

    FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients Favorable Tolerability and Differentiated Safety Profile Observed with

  3. ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine and Initial Data from Phase 1b FORWARD II Triplet Cohort at ESMO

    Conference Call to be Held at 8 a.m. ET on Monday, September 30 ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that full

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved Feb 22 2013 - under priority review
Kadcyla
2nd-line HER2+ Metastatic Breast Cancer
Phase 1b/2 initial data due at ESMO September 2019 noted ORR 83%; CR 17%.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 3 top-line data released March 1, 2019 did not meet primary endpoint. Further Phase 3 trial to be initiated later in 2019 with data due 1H 2022.
Mirvetuximab soravtansine
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 trial did not meet endpoints.
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Endpoint not met - October 2015
Kadcyla GATSBY trial
Cancer - metastatic HER2+ gastric cancer
Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy
Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial
Cancer - 1st-line HER2+ Metastatic Breast Cancer
Phase 1 updated data due 2019.
IMGN632
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Further development to be discontinued - noted June 27, 2019.
IMGN779
Relapsed/refractory acute myeloid leukemia (AML)

Latest News

  1. ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO

    FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of

  2. ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

    FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients Favorable Tolerability and Differentiated Safety Profile Observed with

  3. ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine and Initial Data from Phase 1b FORWARD II Triplet Cohort at ESMO

    Conference Call to be Held at 8 a.m. ET on Monday, September 30 ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that full